title: Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1.
abstract: Host development of human anti-mouse antibodies (HAMA) in response to administered antibodies has been reported as a problem for antibody imaging and therapy. However, radioimmunotherapy has been shown to be effective in patients with B-cell malignancies because their immunodeficient state precludes or delays development of a HAMA response to mouse antibodies. Baseline HAMA activity was assayed in 60 patients with B-lymphocytic non-Hodgkin's lymphoma or chronic lymphocytic leukemia and sequentially in 43 patients who were subsequently treated with radiolabeled Lym-1 antibody. Pre-existing "HAMA" activity was found in 3 (5%) of the 60 patients screened for treatment consideration. The incidence of development of HAMA in the 43 patients treated with multiple doses of radiolabeled Lym-1 antibody was 12 (28%). There was no evidence for an anaphylactoid or related response in the HAMA positive patients. HAMA activity interrupted therapy in 14% of the patients (6 of 43) but did not preclude therapeutic responses to radiolabeled Lym-1 therapy. Medial survival for the HAMA positive patients was longer (18 months) than for those who did not develop HAMA activity (9 months).
authors.affiliation: University of California Davis Medical Center, Sacramento, USA.
authors.forename: G L
authors.initials: GL
authors.lastname: De Nardo
authors.forename: L A
authors.initials: LA
authors.lastname: Kroger
authors.forename: G R
authors.initials: GR
authors.lastname: Mirick
authors.forename: K R
authors.initials: KR
authors.lastname: Lamborn
authors.forename: S J
authors.initials: SJ
authors.lastname: De Nardo
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007114:Immunization; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000401:mortality / Q000532:radiotherapy; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D051379:Mice / Q000276:immunology*; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000009:adverse effects*; D013045:Species Specificity; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007457:Iodine Radioisotopes